

## Supporting Information

# Genome-guided discovery of the first myxobacterial Biarylptide Myxarylin reveals C–N biaryl crosslinking in RiPP biosynthesis

Joachim J. Hug <sup>1,2,†</sup>, Nicolas A. Frank <sup>1,2,†</sup>, Christine Walt <sup>1,2</sup>, Petra Šenica <sup>1,2</sup>,  
Fabian Panter <sup>1,2,3</sup> and Rolf Müller <sup>1,2,3,\*</sup>

- 1     Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, Campus E8 1, 66123 Saarbrücken, Germany;  
Joachim.Hug@helmholtz-hips.de (J.J.H.); Nicolas.Frank@helmholtz-hips.de (N.A.F.); Christine.Walt@helmholtz-hips.de (C.W.); Petra.Senica1@gmail.com (P.Š.); Fabian.Panter@gmail.com (F.P.)
- 2     German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Germany
- 3     Helmholtz International Labs, Campus E8 1, 66123 Saarbrücken, Germany
- \*     Correspondence: rolf.mueller@helmholtz-hips.de
- †     These authors contributed equally to this work.

**Table of Contents**

1	Myxobacterial culture media .....	3
2	Molecular cloning, construction of expression plasmids and genetic investigation.....	6
2.1	Genetic investigations .....	7
2.2	Heterologous production of Myxarylin in <i>M. xanthus</i> DK1622 .....	8
3	Compound Characterization .....	11
3.1	Tandem MS spectra.....	11
3.2	Structure elucidation.....	12
3.2.1	NMR-based structure elucidation.....	12
3.2.2	NMR spectra employed in Myxarylin structure elucidation .....	15
3.2.3	Elucidation of the absolute stereochemistry .....	28
4	References .....	34

# 1 Myxobacterial culture media

**Table S1.** Recipe for VY/2 medium.

VY/2 – Medium			
Amount	Ingredient	Concentration	Supplier
5 g/L	Yeast (entire cells)	-	Deutsche Hefewerke GmbH, Nürnberg, Germany
5 g/L	Soluble Starch	-	Carl Roth GmbH, Karlsruhe, Germany
1 g/L	CaCl <sub>2</sub> • 2H <sub>2</sub> O	-	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
1 g/L	MgSO <sub>4</sub> • 7H <sub>2</sub> O	-	Grüssing GmbH, Filsum, Germany
10 mL/L	TRIS • HCl pH 8	1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
100 µL/L	Sterile Vit. B12 solution (added after autoclaving)	1 mg/mL	Carl Roth GmbH, Karlsruhe, Germany
200 µL/L	Sterile FeNaEDTA solution (added after autoclaving)	8 mg/mL	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
Dissolved in milli-Q. Water, pH adjusted to 7.2 with 1N HCl			

**Table S2.** Recipe for VY medium.

VY – Medium			
Amount	Ingredient	Concentration	Supplier
10 g/L	Yeast (entire cells)	-	Deutsche Hefewerke GmbH, Nürnberg, Germany
5 g/L	Soluble Starch	-	Carl Roth GmbH, Karlsruhe, Germany
1 g/L	CaCl <sub>2</sub> • 2H <sub>2</sub> O	-	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
1 g/L	MgSO <sub>4</sub> • 7H <sub>2</sub> O	-	Grüssing GmbH, Filsum, Germany
10 mL/L	TRIS • HCl pH 8	1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
100 µL/L	Sterile Vit. B12 solution (added after autoclaving)	1 mg/mL	Carl Roth GmbH, Karlsruhe, Germany
200 µL/L	Sterile FeNaEDTA solution (added after autoclaving)	8 mg/mL	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
Dissolved in milli-Q. Water, pH adjusted to 7.2 with 1N HCl			

**Table S3.** Recipe for CFL medium.

CFL – Medium			
Amount	Ingredient	Concentration	Supplier
3 g/L	Tryptone	-	Becton, Dickinson and Company, Sparks, MD, USA
1 g/L	Soytone	-	Becton, Dickinson and Company, Sparks, MD, USA
3.5 g/L	Soluble Starch	-	Carl Roth GmbH, Karlsruhe, Germany
4 g/L	Maltose Monohydrate	-	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
2 g/L	Glucose	-	Carl Roth GmbH, Karlsruhe, Germany
0.5 g/L	CaCl <sub>2</sub> • 2H <sub>2</sub> O	-	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
1 g/L	MgSO <sub>4</sub> • 7H <sub>2</sub> O	-	Grüssing GmbH, Filsum, Germany
10 mL/L	TRIS • HCl pH 8	1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
100 µL/L	Sterile Vit. B12 solution (added after autoclaving)	1 mg/mL	Carl Roth GmbH, Karlsruhe, Germany
200 µL/L	Sterile FeNaEDTA solution (added after autoclaving)	8 mg/mL	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
Dissolved in milli-Q. Water, pH adjusted to 7.5 with 1N KOH			

**Table S4.** Recipe for P medium.

P – Medium			
Amount	Ingredient	Concentration	Supplier
2 g/L	Peptone (Phytone)	-	Becton, Dickinson and Company, Sparks, MD, USA
4 g/L	Procion FM582	-	Hoechst GmbH, Frankfurt, Germany
8 g/L	Soluble Starch	-	Carl Roth GmbH, Karlsruhe, Germany
2 g/L	Glucose	-	Carl Roth GmbH, Karlsruhe, Germany
1 g/L	CaCl <sub>2</sub> • 2H <sub>2</sub> O	-	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
1 g/L	MgSO <sub>4</sub> • 7H <sub>2</sub> O	-	Grüssing GmbH, Filsum, Germany
10 mL/L	TRIS • HCl pH 8	1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
100 µL/L	Sterile Vit. B12 solution (added after autoclaving)	1 mg/mL	Carl Roth GmbH, Karlsruhe, Germany
200 µL/L	Sterile FeNaEDTA solution (added after autoclaving)	8 mg/mL	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
Dissolved in milli-Q. Water, pH adjusted to 7.5 with 1N KOH			

**Table S5.** Recipe for M medium.

M – Medium			
Amount	Ingredient	Concentration	Supplier
10 g/L	Soy Peptone	-	Becton, Dickinson and Company, Sparks, MD, USA
10 g/L	Maltose monohydrate	-	Becton, Dickinson and Company, Sparks, MD, USA
1 g/L	CaCl <sub>2</sub> • 2H <sub>2</sub> O	-	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
1 g/L	MgSO <sub>4</sub> • 7H <sub>2</sub> O	-	Grüssing GmbH, Filsum, Germany
10 mL/L	TRIS • HCl pH 8	1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
100 µL/L	Sterile Vit. B12 solution (added after autoclaving)	1 mg/mL	Carl Roth GmbH, Karlsruhe, Germany
200 µL/L	Sterile FeNaEDTA solution (added after autoclaving)	8 mg/mL	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
Dissolved in milli-Q. Water, pH adjusted to 7.5 with 1N KOH			

**Table S6.** Recipe for YM medium.

YM – Medium			
Amount	Ingredient	Concentration	Supplier
3 g/L	Yeast extract	-	Becton, Dickinson and Company, Sparks, MD, USA
3 g/L	Malt extract	-	Becton, Dickinson and Company, Sparks, MD, USA
5 g/L	Peptone (Phytone)	-	Becton, Dickinson and Company, Sparks, MD, USA
10 g/L	Glucose	-	Carl Roth GmbH, Karlsruhe, Germany
1 mL/L	K <sub>2</sub> H <sub>2</sub> PO <sub>4</sub> buffer pH 8.0	0.8 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
1 g/L	MgSO <sub>4</sub> • 7H <sub>2</sub> O	-	Grüssing GmbH, Filsum, Germany
10 mL/L	TRIS • HCl pH 8	1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
100 µL/L	Sterile Vit. B12 solution (added after autoclaving)	1 mg/mL	Carl Roth GmbH, Karlsruhe, Germany
200 µL/L	Sterile FeNaEDTA solution (added after autoclaving)	8 mg/mL	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
Dissolved in milli-Q. Water, pH adjusted to 7.5 with 1N KOH			

**Table S7.** Recipe for CTT medium.

CTT – Medium			
Amount	Ingredient	Concentration	Supplier
10 g/L	Casitone	-	Becton, Dickinson and Company, Sparks, MD, USA
10 mL/L	MgSO <sub>4</sub> • 7H <sub>2</sub> O	0.8 M	Grüssing GmbH, Filsum, Germany
1 mL/L	K <sub>x</sub> H <sub>y</sub> PO <sub>4</sub> buffer pH 8.0	0.1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
10 mL/L	TRIS • HCl pH8	1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
100 µL/L	Sterile Vit. B12 solution (added after autoclaving)	1 mg/mL	Carl Roth GmbH, Karlsruhe, Germany
200 µL/L	Sterile FeNaEDTA solution (added after autoclaving)	8 mg/mL	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
Dissolved in milli-Q. Water, pH adjusted to 7.6 with 1N KOH			

**Table S8.** Recipe for AMB medium.

AMB– Medium			
Amount	Ingredient	Concentration	Supplier
2.5 g/L	Casitone	-	Becton, Dickinson and Company, Sparks, MD, USA
5 g/L	Soluble starch	-	Carl Roth GmbH, Karlsruhe, Germany
10 mL/L	MgSO <sub>4</sub> • 7H <sub>2</sub> O	0.8 M	Grüssing GmbH, Filsum, Germany
1 mL/L	K <sub>x</sub> H <sub>y</sub> PO <sub>4</sub> buffer pH 8.0	0.1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
10 mL/L	TRIS • HCl pH 8.0	1 M	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
100 µL/L	Sterile Vit. B12 solution (added after autoclaving)	1 mg/mL	Carl Roth GmbH, Karlsruhe, Germany
200 µL/L	Sterile FeNaEDTA solution (added after autoclaving)	8 mg/mL	Sigma Aldrich Chemie GmbH, Taufkirchen, Germany
Dissolved in milli-Q. Water, pH adjusted to 7.6 with 1N KOH			

## 2 Molecular cloning, construction of expression plasmids and genetic investigation

**Table S9.** List of oligonucleotides used in this study.

No.	Primer name	Primer sequence 5'–3'
1	Fw_mx8_PagI	ATAT <b>T</b> CATGAGGCCATCGTCGAAAGAGTCG
2	Rv_mx8_ScaI	ATATAGTACTAGGACTCCTCTGGCTGGGTG
3	Fw_An_d48_NdeI	ATATCATATGA <b>A</b> CTACCTGCACTGAGAGGAGCCTCCGTGCCCA
4	Rv_An_d48_EcoRI	TATATGA <b>A</b> TTTCGAGGCGGCGTAGCCCTCA
5	Mx8-attP-up2	CGACGGTGCCGACAAATAC
6	Mx8-attB-up2	GCGCACTGGACCATCACGTC
7	Mx8-attP-down	GGCTTGTGCCAGTCAACTGCG
8	Mx8-attB-down	CGGATAGCTCAGCGGTAGAG

Restriction sites in bold, *bytA* and *bytO* start are underlined, RBS of *bytO* in yellow.

**Table S10.** List of oligonucleotides for sequencing used in this study.

No.	Primer name	Primer sequence 5'–3'
1	P <sub>van</sub> _Seq1	TGTCAAGCTGCTGTTTTTCGC
2	M13-29R	CAGGAAACAGCTATGACC
3	BiarylSeq1	GAGGCGGCGTAGCCCTCA
4	BiarylSeq2	GAGGAGCCTCCGTGCCCA

**Table S11.** List of PCR-amplified constructs.

No.	PCR product name/characteristics	Size [bp]	template	Primers used
1	mx8_integrase gene_PagI_ScaI	1945	pBen39	primer No.1 primer No.2
2	An_d48_ <i>bytAOZ</i>	2034	gDNA from <i>P. fallax</i> An d48	primer No.1 primer No.2

**Table S12.** List of plasmids used in this study.

No.	Plasmid name/ characteristic	Size [kb]	Function	Reference
1	pFP <sub>van</sub> _pcyA	6.181	pCR 2.1 TOPO derivative; used as backbone for heterologous expression of <i>bytAO</i>	[1]
2	pBen39	7.616	mx8_integrase fragment mobilized on pUC-based plasmid pBen38/ <i>kanR</i> , <i>ampR</i>	unpublished


**Table S13.** List of genetic constructs generated in this study.

No.	Plasmid name	Construction details/ characteristics
1	pFP <sub>Van</sub> <sub>pcyA</sub> _mx8	Construct obtained by conventional restriction ligation of plasmid pFP <sub>Van</sub> <sub>pcyA</sub> and PCR product No. 1
2	pFP <sub>Van</sub> <sub>bytAOZ</sub> _mx8	Construct obtained by conventional restriction ligation of construct No. 1 and PCR product No. 2

## 2.1 Genetic investigations



**Figure S1.** Amino acid alignment of myxobacterial BytO homologs from *Pyxidicoccus* sp. CA032A (*bytO*\_CA032A\_YLH) and *Pyxidicoccus fallax* An d48 (*bytO*\_And48\_YLH). Pairwise identity and identical sites: 91.5%.



**Figure S2.** Amino acid alignment of BytO homologs from *Planomonospora* sp. ID107089 (*bytO*\_ID107089\_YFH), *Planomonospora* sp. ID82291 (*bytO*\_ID82291\_YYH) and *Pyxidicoccus fallax* An d48 (*bytO*\_And48\_YLH). Pairwise identity: 59.5%, Identical sites: 40.7%.



**Figure S3.** Nucleotide sequence and different orfs of *bytO* in *Pyxidicoccus fallax* An d48 (A) and *Pyxidicoccus* sp. CA032A (B) that are varying in nucleotide length. The length of a hypothetical *bytO* gene in *Pyxidicoccus* sp. CA032A is limited by the presence of a stop codon in the same translational frame. *Pyxidicoccus fallax* An d48 features in this genetic locus a single nucleotide deletion, which causes a frame shift (blue dashed box). Therefore two hypothetical longer orfs of *bytO* could be possibly expressed. Nevertheless, the most likely start of the myxobacterial *bytO* is in both nucleotide sequences labeled as *bytO* authentic for the following two reasons; firstly, a putative RBS (red dashed box) is only present in front of *bytO* authentic, and secondly in *Pyxidicoccus* sp. CA032A, only *bytO* authentic can be expressed, since any other longer version does not feature an appropriate start codon.


## 2.2 Heterologous production of Myxarylin in *M. xanthus* DK1622

To express the identified Myxarylin-BGC in *M. xanthus* DK1622, an expression vector was constructed based on the plasmid pFP<sub>van</sub><sub>pcyA</sub>. [1] To enable efficient genomic integration of the expression plasmid, the *mx8* integrase gene originating from the bacteriophage Mx8 was PCR-amplified (Phusion™ High-Fidelity polymerase, Thermo Fisher Scientific) from pBen39 and the resulting PCR product subcloned into pFP<sub>van</sub><sub>pcyA</sub> via conventional restriction ligation (PacI, ScaI). The resulting plasmid pFP<sub>van</sub><sub>pcyA</sub><sub>mx8</sub> (genetic construct 1) was subsequently used to incorporate the PCR-amplified Myxarylin-BGC (An\_d48\_*bytAOZ*, PCR product 2) from *P. fallax* An d48, which led to the final expression vector pFP<sub>van</sub><sub>bytAOZ</sub><sub>mx8</sub> (genetic construct 2). The PCR-amplified operon (An\_d48\_*bytAOZ*, PCR product 2) differs from the natural sequence in that sense, it lacks the intergenic region between *bytA* and *bytO* (termed *bytAO*\_intergenic region, **Figure S3**).




**Figure S4.** Nucleotide sequence encoding the precursor peptide BytA, the intergenic region termed *bytAO*, the putative ribosome binding site of *bytO*, and the first seven nucleotides encoding the cytochrome P450-dependent enzyme BytO.

Since the intergenic region *bytAO* features *in silico* the formation of secondary structures (**Figure S5**) – resembling those of known transcriptional terminators such as the *tD1* terminator from *M. xanthus* bacteriophage Mx8 [2] – the heterologous expression construct was designed in a way to omit this 90 bp intergenic region and only includes 11 bp in which a putative ribosome binding site is incorporated (..AGGA..) (**Figure S6**).




**Figure S5.** Predicted secondary structure of the 90 bp intergenic region *bytAO* (A), and the hair pin structure of the previously described 49 bp transcriptional terminator *tD1* (B).

A




B




**Figure S6.** A) Nucleotide sequence and annotation of the primer Fw\_An\_d48\_NdeI (Primer 3, 43 bp). Primer 3 comprises at the 5' end extensions which include a protection site for the NdeI restriction site, the authentic *bytA* nucleotide sequence, the identified RBS site of *bytO* and the first seven nucleotides of the gene encoding BytO. Within Primer 3, 18 bp at the 3' end is responsible for the site-specific annealing (termed Fw\_An\_d48\_NdeI\_bind). B) The associated reverse primer Rv\_An\_d48\_EcoRI (Primer 4, 29 bp), was designed in a way that the genetic region downstream of *bytZ* remained unmodified in the respective PCR product. Hence, Primer 4 features at the 5' end an extension for the EcoRI restriction site including a 5 bp protection site and 18 bp at the 3' end for site-specific annealing (termed Rv\_An\_d48\_EcoRI\_bind).

## 3 Compound Characterization

### 3.1 Tandem MS spectra



**Figure S7.** Tandem MS spectrum of **1** (collision energy: 35.0 eV). Leucine loss ( $\Delta m/z = 113.0841$ ) is visible e.g. between 416.2290  $m/z$  and 303.1452  $m/z$  (err. 0.0003  $m/z$ ) or 370.2232  $m/z$  and 257.1398  $m/z$  (err. 0.0007  $m/z$ ).



**Figure S8.** Tandem MS spectrum of **2** (collision energy: 35.9 eV).

## 3.2 Structure elucidation

### 3.2.1 NMR-based structure elucidation


**Table S14.** NMR spectroscopic data of **2** measured in methanol- $d_4$  at 700/175 MHz.

#	$\Delta^{13}\text{C}$ [PPM]	$\Delta^1\text{H}$ [PPM], MULT ( $J$ [HZ])	$\Delta^{15}\text{N}$ [PPM]	COSY	HMBC	SEL NOESY	$^1\text{H}$ - $^{15}\text{N}$ HMBC
1	171.8	-	-	-	-	n.m.	-
2	59.7	4.66, m	-	3	-	n.m.	-
3	34.2	3.55,2.56, dd (15.19, 11.77)	-	2,3,5	1,2,5,9	n.m.	-
4	131.1	-	-	-	-	n.m.	-
5	126.1	6.84, m	-	-	-	n.m.	-
6	-	-	-	-	-	n.m.	-
7	149.7	-	-	-	-	n.m.	-
8	118.1	6.91, brs	-	9	4,5,7,9	9	-
9	130.2	7.03, d (8.13)	-	8	3,5,7,8	n.m.	-
10	157.6	-	-	-	-	n.m.	-
11	81.9	-	-	-	-	n.m.	-
12,13,14	28.8	1.48, s	-	-	11,12,13,14-	n.m.	-
15	30.7	2.90, s	-	-	2,10	n.m.	16
1'	173.7	-	-	-	-	n.m.	-
2'	52.8	4.86, s	-	3'	1,1',3',4'	n.m.	-
3'	43.7	1.58, m	-	2',5',6'	4'	n.m.	-
4'	26.1	1.60, m	-	5',6'	-	n.m.	-
5',6'	23.8	0.94, m	-	3'	-	n.m.	-
1''	177.8	-	-	-	-	n.m.	-
2''	55.2	4.61, dd (12.62, 2.78)	-	3''	1',1'',3'',4''	n.m.	-
3''	33.0	3.32,2.82, dd (16.47, 12.62)	-	2'',3'',6''	1'',2'',4'',6''	n.m.	18,20
4''	139.3	-	-	-	-	n.m.	-
5''	138.5	7.94, s	-	6''	4'',6''	-	19,20
6''	118.9	6.89, s	-	3'',5''	4'',5''	-	19,20
16	-	-	84.7	-	-	n.m.	-
17	-	-	-	-	-	n.m.	-
18	-	-	123.1	-	-	n.m.	-
19	-	-	174.6	-	-	n.m.	-
20	-	-	247.3	-	-	n.m.	-


n.m.: not measured

**Table S15.** NMR spectroscopic data of **1** measured in DMSO-d<sub>6</sub> at 700/175 MHz.

#	$\Delta^{13}\text{C}$ [PPM]	$\Delta^1\text{H}$ [PPM], MULT ( <i>J</i> [HZ])	COSY	HMBC
<b>1</b>	166.6	-	-	-
<b>2</b>	61.1	4.08, m	3,16	-
<b>3</b>	33.1	3.16, m	2,5,9	1,2,5,9
<b>4</b>	-	-	-	-
<b>5</b>	127.8	6.81, d (2.25)	3,9	3,7,9
<b>6</b>	125.3	-	-	-
<b>7</b>	149.3	-	-	-
<b>8</b>	117.1	7.08, d (8.34)	9	6,7
<b>9</b>	131.8	7.23, dd (8.24,2.25)	3,5,8	3,7,8
<b>15</b>	31.3	2.50, m	16	2
<b>1'</b>	171.9	-	-	-
<b>2'</b>	51.5	4.71, td (9.06,5.4)	3',17	-
<b>3'</b>	42.1	1.54,1.48, m	2',4'	1',2',4',5',6'
<b>4'</b>	24.1	1.67, m	5',6'	3',5',6'
<b>5'</b>	22.7	0.93, d (6.63)	4'	3',4',6'
<b>6'</b>	21.6	0.90 d (6.63)	-	4',5'
<b>1''</b>	171.1	-	-	-
<b>2''</b>	50.6	4.58, ddd (12.25, 9.52, 2.78)	3'',18	-
<b>3''</b>	27.0	3.35,2.87, dd (15.19, 12.41)	2'',6''	1'',2'',4'',6''
<b>4''</b>	130.6	-	-	-
<b>5''</b>	135.6	9.35, s	6''	4'',6''
<b>6''</b>	120.4	7.16, s	3'',5''	4'',5''
<b>16</b>	-	8.79, brs	2	-
<b>17</b>	-	9.21, d (8.56)	2'	1
<b>18</b>	-	8.86, d (9.52)	2''	1'




**Figure S9.** Chemical structure and atom numbering of **2**. COSY correlations are represented as bold lines, HMBC correlations are marked with arrows.




**Figure S10.** Chemical structure and atom numbering of **1**. COSY correlations are represented as bold lines, HMBC correlations are marked with arrows.


### 3.2.2 NMR spectra employed in Myxarylin structure elucidation




**Figure S11.** <sup>1</sup>H spectrum of **2** measured in methanol-d<sub>4</sub> at 700 MHz.




**Figure S12.**  $^{13}\text{C}$  spectrum of **2** measured in methanol- $\text{d}_4$  at 175 MHz.




**Figure S13.** HSQC spectrum of **2** measured in methanol- $\text{d}_4$  at 700 ( $^1\text{H}$ ) and 175 ( $^{13}\text{C}$ ) MHz.




**Figure S14.** COSY spectrum of **2** measured in methanol- $d_4$  at 700 MHz.




**Figure S15.** HMBC spectrum of **2** measured in methanol- $d_4$  at 700 ( $^1\text{H}$ ) and 175 ( $^{13}\text{C}$ ) MHz.




**Figure S16.**  $^1\text{H}$ - $^{15}\text{N}$  HMBC spectrum of **2** measured in methanol- $\text{d}_4$  at 700 ( $^1\text{H}$ ) and 175 ( $^{15}\text{N}$ ) MHz.




**Figure S17.** Spectrum of 2 exciting at  $\delta(^1\text{H}) = 6.91$  ppm with a distance of 20.32 Hz in methanol- $\text{d}_4$  at 700 MHz.




**Figure S18.** Selective 1D NOESY spectrum of **2** exciting at  $\delta(^1\text{H}) = 7.94$  ppm with a distance of 17.20 Hz in methanol- $\text{d}_4$  at 700 MHz.




**Figure S19.**  $^1\text{H}$  spectrum of **1** measured in  $\text{DMSO}-d_6$  at 700 MHz.




**Figure S20.**  $^{13}\text{C}$  spectrum of **1** measured in  $\text{DMSO}-d_6$  at 175 MHz.



**Figure S21.** HSQC spectrum of **1** measured in  $\text{DMSO}-d_6$  at 700 ( $^1\text{H}$ ) and 175 ( $^{13}\text{C}$ ) MHz.




**Figure S22.** COSY spectrum of **1** measured in DMSO-*d*<sub>6</sub> at 700 MHz.




**Figure S23.** HMBC spectrum of **1** measured in  $\text{DMSO-}d_6$  at 700 ( $^1\text{H}$ ) and 175 ( $^{13}\text{C}$ ) MHz.


### 3.2.3 Elucidation of the absolute stereochemistry




**Figure S24.** Marfey's derivatization reaction of L-leucine standard with L- respective D-(1-fluoro-2,4-dinitrophenyl-5-leucine amide) (FDLA).




**Figure S25.** HPLC-MS extracted ion chromatograms (EICs) of 426.19833  $m/z$  with a width of 0.005  $m/z$  from Marfey's derivatization reaction with commercial L-leucine standard and hydrolyzed **1**. Highlighted in green: L-L-product peaks; highlighted in blue: D-L-product peaks.





**Figure S26.** Marfey's derivatization reaction of L-histidine standard with L- respective D-(1-fluoro-2,4-dinitrophenyl-5-leucine amide) (FDLA).



**Figure S27.** HPLC-MS extracted ion chromatograms (EICs) of 450.17317  $m/z$  with a width of 0.005  $m/z$  from Marfey's derivatization reaction with commercial L-histidine standard and hydrolyzed 1. Highlighted in green: D-L-product peaks; highlighted in blue: L-L-product peaks.



**Figure S28.** Marfey's derivatization reaction of L-tyrosine standard with L- respective D-(1-fluoro-2,4-dinitrophenyl-5-leucine amide) (FDLA). In this case, we mainly observed the double derivatized product as shown above.



**Figure S29.** HPLC-MS extracted ion chromatograms (EICs) of 770.27401  $m/z$  with a width of 0.005  $m/z$  from Marfey's derivatization reaction with commercial L-tyrosine standard and hydrolyzed **1**. Highlighted in green: L-L-L-product peaks; highlighted in blue: D-L-D-product peaks.

## 4 References

1. Panter, F.; Krug, D.; Baumann, S.; Müller, R. Self-resistance guided genome mining uncovers new topoisomerase inhibitors from myxobacteria. *Chem. Sci.* **2018**, *9*, 4898–4908, doi:10.1039/C8SC01325J.
2. Magrini, V.; Creighton, C.; Youderian, P. Site-specific recombination of temperate *Myxococcus xanthus* phage Mx8: genetic elements required for integration. *J. Bacteriol.* **1999**, *181*, 4050–4061, doi:10.1128/jb.181.13.4050-4061.1999.